Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies

Drug Discovery Today

Volumn 20, Issue 9, 2015, Pages 1127-1134

  Borch, Troels H ^a   Donia, Marco ^a   Andersen, Mads H ^a   Svane, Inge M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ANTINEOPLASTIC AGENT; AVELUMAB; BMS 936559; DURVALUMAB; IPILIMUMAB; MEDI 0860; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; HUMAN; IMMUNE SYSTEM; METASTATIC MELANOMA; NONHUMAN; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84941025887     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.07.003     Document Type: Review

References (84)

1. K. Lafferty, and A. Cunningham A new analysis of allogeneic interactions Aust. J. Exp. Biol. Med. Sci. 53 1975 27 42
2. G.J. Freeman, and A.H. Sharpe A new therapeutic strategy for malaria: targeting T cell exhaustion Nat. Immunol. 13 2012 113 115
3. D.R. Leach, and et al. Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
4. F. Hodi, and S. O'Day Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
5. D. Schadendorf, and et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J. Clin. Oncol. 2015 10.1200/JCO.2014.56.2736
6. Y. Ishida, and et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J. 1 1992 3887 3895
7. X. Zhang, and et al. Structural and functional analysis of the costimulatory receptor programmed death-1 Immunity 20 2004 337 347
8. Y. Agata, and et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int. Immunol. 8 1996 765 772
9. E.J. Wherry T cell exhaustion Nat. Immunol. 131 2011 492 499
10. H. Dong, and et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med. 5 1999 1365 1369
11. Y. Latchman, and et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat. Immunol. 2 2001 261 268
12. M.J.I. Ansari, and et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice J. Exp. Med. 198 2003 63 69
13. H. Frebel, and et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice J. Exp. Med. 209 2012 2485 2499
14. T. Pentcheva-Hoang, and et al. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability Proc. Natl. Acad. Sci. U. S. A. 104 2007 17765 17770
15. R.V. Parry, and et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol. Cell. Biol. 25 2005 9543 9553
16. F. Bennett, and et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses J. Immunol. 170 2003 711 718
17. M. Tsuda, and et al. Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA Biochem. Biophys. Res. Commun. 330 2005 263 270
18. N. Rodig, and et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis Eur. J. Immunol. 33 2003 3117 3126
19. S-K. Seo, and et al. Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway Life Sci. 112 2014 82 89
20. M.E. Keir, and et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance J. Exp. Med. 203 2006 883 895
21. R. Deng, and et al. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease J. Immunol. 194 2014 560 574
22. L.M. Francisco, and et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J. Exp. Med. 206 2009 3015 3029
23. S-Y. Tseng, and et al. B7-Dc, a new dendritic cell molecule with potent costimulatory properties for T cells J. Exp. Med. 193 2001 839 846
24. T. Yamazaki, and et al. Expression of programmed death 1 ligands by murine T cells and APC J. Immunol. 169 2002 5538 5545
25. P. Loke, and J.P. Allison PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 5336 5341
26. Y. Xiao, and et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance J. Exp. Med. 211 2014 943 959
27. M.D. Vesely, and et al. Natural innate and adaptive immunity to cancer Annu. Rev. Immunol. 29 2011 235 271
28. R.S. Herbst, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
29. S. Strome, and et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res. 63 2003 6501 6505
30. R.H. Thompson, and et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc. Natl. Acad. Sci. U. S. A. 101 2004 17174 17179
31. J. Hamanishi, and et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 104 2007 3360 3365
32. T. Nomi, and et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin. Cancer Res. 13 2007 2151 2157
33. S. Sun, and et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients Cancer Immunol. Immunother. 63 2014 395 406
34. J. Matsuzaki, and et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 107 2010 7875 7880
35. W. Peng, and et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines Cancer Res. 72 2012 5209 5218
36. C. Blank, and et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int. J. Cancer 119 2006 317 327
37. M. Mkrtichyan, and et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets J. Immunol. 189 2012 2338 2347
38. S. Munir, and et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients Cancer Res. 73 2013 1764 1776
39. S. Munir, and et al. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells Leukemia 27 2013 2251 2253
40. S.M. Ahmad, and et al. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway Leukemia 28 2014 236 238
41. S.M. Ahmad, and et al. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity Blood Cancer J. 4 2014 e230
42. O. Hamid, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
43. C. Robert, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 6736 2014 1 9
44. C. Robert, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N. Engl. J. Med. 372 2015 2521 2532
45. K. Muro, and et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced gastric cancer Ann. Oncol. 25 Suppl 4 2014 LBA15
46. E. Plimack, and et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer Ann. Oncol. 25 Suppl 4 2014 LBA23
47. L.Q.M. Chow, and et al. A phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (pts) with human papilloma virus (HPV)-positive and negative head and neck cancer (HNC) Ann. Oncol. 25 Suppl 4 2014 LBA31
48. E. Garon, and et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1 expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC) Ann. Oncol. 25 Suppl. 4 2014 LBA43
49. J.R. Brahmer, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol. 28 2010 3167 3175
50. S.L. Topalian, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
51. J.S. Weber, and et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J. Clin. Oncol. 31 2013 4311 4318
52. S.M. Ansell, and et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N. Engl. J. Med. 372 2015 311 319
53. R.J. Motzer, and et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J. Clin. Oncol. 2014 10.1200/JCO.2014.59.0703
54. J.S. Weber, and et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy Ann. Oncol. 25 Suppl 4 2014 LBA3
55. C. Robert, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N. Engl. J. Med. 372 2015 320 330
56. J. Brahmer, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N. Engl. J. Med. 2015 10.1056/NEJMoa1504627
57. M.a. Curran, and et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U. S. A. 107 2010 4275 4280
58. J.D. Wolchok, and et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
59. M. Sznol, and et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) J. Clin. Oncol. 32 2014 LBA9003
60. J. Larkin, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 373 2015 23 34
61. H-J. Hammers, and et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) J. Clin. Oncol. 32 2014 4504
62. S.J. Antonia, and et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results J. Clin. Oncol. 32 2014 8023
63. R. Berger, and et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin. Cancer Res. 14 2008 3044 3051
64. P. Armand, and et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J. Clin. Oncol. 31 2013 4199 4206
65. J.R. Westin, and et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Lancet Oncol. 15 2014 69 77
66. M. Atkins, and et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma J. Clin. Oncol. 32 2014 9001
67. J.R. Brahmer, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
68. T. Powles, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
69. K.M. Mahoney, and et al. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma Clin. Ther. 37 2015 764 782
70. D.T. Le, and et al. PD-1 blockade in tumors with mismatch-repair deficiency N. Engl. J. Med. 372 2015 2509 2520
71. S. Spranger, and T. Gajewski Rational combinations of immunotherapeutics that target discrete pathways J. Immunother. Cancer 1 2013 16
72. S.J. Mandl, and et al. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy J. Immunother. Cancer 2 2014 34
73. R.B. Sørensen, and et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators Blood 117 2011 2200 2210
74. L. Karyampudi, and et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody Cancer Res. 74 2015 2974 2985
75. S. Rosenberg, and et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res. 17 2011 4550 4557
76. I.M. Svane, and E.M. Verdegaal Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol. Immunother. 63 2014 1081 1091
77. A. Gros, and et al. PD-1 identifies the patient-specific infiltrating human tumors J. Clin. Invest. 124 2014 2246 2259
78. L. Galluzzi, and et al. The secret ally: immunostimulation by anticancer drugs Nat. Rev. Drug Discov. 11 2012 215 233
79. K.A. Pilones, and et al. Combination of radiotherapy and immune checkpoint inhibitors Semin. Radiat. Oncol. 25 2015 28 33
80. A. Ribas, and J.D. Wolchok Combining cancer immunotherapy and targeted therapy Curr. Opin. Immunol. 25 2013 291 296
81. A. Ribas, and et al. Hepatotoxicity with combination of ipilimumab and vemurafenib N. Engl. J. Med. 368 2013 1365 1366
82. T. Okazaki, and et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat. Immunol. 14 2013 1212 1218
83. J. Lutzky, and S. Antonia A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors J. Clin. Oncol. 2014 2014 ASCO Annu. Meet. Abstr. 32, Abstract 3001
84. C. Heery, and et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies J. Clin. Oncol. 2014 2014 ASCO Annu. Meet. Abstr. 32, Abstract 3064